NASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free PRCT Stock Alerts $63.00 +2.64 (+4.37%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$60.14▼$63.2250-Day Range$45.73▼$64.3152-Week Range$24.83▼$65.00Volume442,360 shsAverage Volume545,234 shsMarket Capitalization$3.24 billionP/E RatioN/ADividend YieldN/APrice Target$61.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get PROCEPT BioRobotics alerts: Email Address PROCEPT BioRobotics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2.9% Downside$61.20 Price TargetShort InterestBearish11.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 31 Articles This WeekInsider TradingSelling Shares$5.29 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.96) to ($1.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.52 out of 5 starsMedical Sector856th out of 915 stocksSurgical & Medical Instruments Industry91st out of 96 stocks 1.5 Analyst's Opinion Consensus RatingPROCEPT BioRobotics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePROCEPT BioRobotics has only been the subject of 3 research reports in the past 90 days.Read more about PROCEPT BioRobotics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.04% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in PROCEPT BioRobotics has recently increased by 15.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRCT. Previous Next 3.0 News and Social Media Coverage News SentimentPROCEPT BioRobotics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 31 news articles for PROCEPT BioRobotics this week, compared to 4 articles on an average week.Search Interest2 people have searched for PRCT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,289,099.00 in company stock.Percentage Held by Insiders19.60% of the stock of PROCEPT BioRobotics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PROCEPT BioRobotics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.96) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -29.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -29.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 11.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PROCEPT BioRobotics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About PROCEPT BioRobotics Stock (NASDAQ:PRCT)PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Read More PRCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRCT Stock News HeadlinesMay 7, 2024 | insidertrades.comThomas M. Krummel Sells 20,000 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) StockMay 4, 2024 | insidertrades.comInsider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Sells 30,432 Shares of StockMay 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 8, 2024 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) PT Raised to $75.00May 8, 2024 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) PT Raised to $75.00 at Piper SandlerMay 7, 2024 | americanbankingnews.comPROCEPT BioRobotics Co. (NASDAQ:PRCT) Director Thomas M. Krummel Sells 20,000 SharesMay 7, 2024 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Trading Down 4.3% After Insider SellingMay 6, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Fulgent Genetics (FLGT), Cigna (CI) and PROCEPT BioRobotics (PRCT)May 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and PROCEPT BioRobotics (PRCT)May 6, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On PROCEPT BioRoboticsMay 6, 2024 | globenewswire.comReal-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaMay 6, 2024 | americanbankingnews.comBrokers Set Expectations for PROCEPT BioRobotics Co.'s Q2 2024 Earnings (NASDAQ:PRCT)May 5, 2024 | americanbankingnews.comAlaleh Nouri Sells 30,432 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) StockMay 4, 2024 | finance.yahoo.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price TargetsMay 4, 2024 | americanbankingnews.comQ2 2024 Earnings Forecast for PROCEPT BioRobotics Co. Issued By William Blair (NASDAQ:PRCT)May 3, 2024 | finance.yahoo.comPROCEPT BioRobotics First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | finance.yahoo.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q1 2024 Earnings Call TranscriptMay 3, 2024 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 52-Week High After Better-Than-Expected EarningsMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Cross Country Healthcare (CCRN) and CVS Health (CVS)May 2, 2024 | finance.yahoo.comPROCEPT BioRobotics Corp (PRCT) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...May 1, 2024 | markets.businessinsider.comBuy Rating Affirmed on PROCEPT BioRobotics’ Strong Performance and Promising Growth TrajectoryMay 1, 2024 | investorplace.comPRCT Stock Earnings: PROCEPT BioRobotics Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | finance.yahoo.comBiotech Leader Procept BioRobotics Jumps Past Buy Point On EarningsMay 1, 2024 | globenewswire.comPROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceMay 1, 2024 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) and Autonomix Medical (NASDAQ:AMIX) Critical ReviewApril 30, 2024 | markets.businessinsider.comHere's what Wall Street expects from PROCEPT BioRobotics's earningsSee More Headlines Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/09/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PRCT CUSIPN/A CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees626Year FoundedN/APrice Target and Rating Average Stock Price Target$61.20 High Stock Price Target$75.00 Low Stock Price Target$37.00 Potential Upside/Downside-2.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,900,000.00 Net Margins-66.12% Pretax Margin-66.12% Return on Equity-41.35% Return on Assets-27.92% Debt Debt-to-Equity Ratio0.19 Current Ratio8.52 Quick Ratio7.44 Sales & Book Value Annual Sales$136.19 million Price / Sales23.79 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book11.33Miscellaneous Outstanding Shares51,420,000Free Float41,345,000Market Cap$3.24 billion OptionableOptionable Beta0.95 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Reza Zadno Ph.D. (Age 69)President, CEO & Director Comp: $1.13MMr. Kevin Waters (Age 47)Executive VP & CFO Comp: $680.11kMs. Alaleh Nouri (Age 45)EVP, Chief Legal Officer & Corporate Secretary Comp: $605.84kMr. Hisham Shiblaq (Age 48)Executive VP & Chief Commercial Officer Comp: $645.95kMr. Mohan F. Sancheti (Age 60)Senior Vice President of Operations Mr. Barry TemplinExecutive VP of Technology & Clinical DevelopmentMr. Matthew James Bacso C.F.A.Vice President of Investor RelationsMs. Stacey L. Porter (Age 48)Chief People Officer Mr. Bijesh ChandranSenior Vice President of Regulatory Affairs & Quality AssuranceMore ExecutivesKey CompetitorsiRhythm TechnologiesNASDAQ:IRTCAxonicsNASDAQ:AXNXTandem Diabetes CareNASDAQ:TNDMInari MedicalNASDAQ:NARIICU MedicalNASDAQ:ICUIView All CompetitorsInsiders & InstitutionsBlair William & Co. ILBought 429,793 shares on 5/9/2024Ownership: 0.836%Lord Abbett & CO. LLCBought 71,106 shares on 5/9/2024Ownership: 0.491%Mitsubishi UFJ Asset Management Co. Ltd.Sold 735 shares on 5/9/2024Ownership: 0.030%BNP PARIBAS ASSET MANAGEMENT Holding S.A.Bought 51,305 shares on 5/8/2024Ownership: 1.221%ProShare Advisors LLCBought 570 shares on 5/8/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions PRCT Stock Analysis - Frequently Asked Questions Should I buy or sell PROCEPT BioRobotics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRCT shares. View PRCT analyst ratings or view top-rated stocks. What is PROCEPT BioRobotics' stock price target for 2024? 7 Wall Street analysts have issued 1-year price targets for PROCEPT BioRobotics' stock. Their PRCT share price targets range from $37.00 to $75.00. On average, they predict the company's stock price to reach $61.20 in the next twelve months. This suggests that the stock has a possible downside of 2.9%. View analysts price targets for PRCT or view top-rated stocks among Wall Street analysts. How have PRCT shares performed in 2024? PROCEPT BioRobotics' stock was trading at $41.91 at the beginning of the year. Since then, PRCT shares have increased by 50.3% and is now trading at $63.00. View the best growth stocks for 2024 here. When is PROCEPT BioRobotics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our PRCT earnings forecast. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Co. (NASDAQ:PRCT) released its quarterly earnings results on Wednesday, May, 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.04. The company earned $44.50 million during the quarter, compared to analyst estimates of $41.58 million. PROCEPT BioRobotics had a negative net margin of 66.12% and a negative trailing twelve-month return on equity of 41.35%. The company's quarterly revenue was up 82.4% on a year-over-year basis. During the same period last year, the company posted ($0.63) EPS. What ETFs hold PROCEPT BioRobotics' stock? ETFs with the largest weight of PROCEPT BioRobotics (NASDAQ:PRCT) stock in their portfolio include Innovator IBD Breakout Opportunities ETF (BOUT), Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE), Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ), ALPS Disruptive Technologies ETF (DTEC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Small Cap Growth AlphaDEX Fund (FYC) and Principal Healthcare Innovators ETF (BTEC). What guidance has PROCEPT BioRobotics issued on next quarter's earnings? PROCEPT BioRobotics issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $213.5 million-$213.5 million, compared to the consensus revenue estimate of $210.2 million. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $126 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? PROCEPT BioRobotics' stock is owned by a number of institutional and retail investors. Top institutional investors include BNP PARIBAS ASSET MANAGEMENT Holding S.A. (1.22%), Blair William & Co. IL (0.84%), Mirae Asset Global Investments Co. Ltd. (0.77%), Lord Abbett & CO. LLC (0.49%), Allspring Global Investments Holdings LLC (0.39%) and Lisanti Capital Growth LLC (0.20%). Insiders that own company stock include Alaleh Nouri, Frederic H Moll, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRCT) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaProof that the Musk/Bezos rivalry is about to hit a new levelInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
